🫁
Our lung cancer program focuses on targeted therapy for driver mutations common in South Asian never-smokers and advanced immunotherapy approaches.
Learn MoreOptimizing treatment sequencing for EGFR-mutant and ALK-rearranged non-small cell lung cancer using next-generation TKIs.
Circulating tumour DNA assays for early detection, treatment response monitoring, and resistance mechanism identification.
Identifying predictive biomarkers for PD-L1 checkpoint inhibitor response in Indian lung cancer populations.
Investigating environmental and genetic risk factors driving the rising incidence of lung cancer among non-smoking Indian women.
NCT06234506
RecruitingPI: Dr. Arvind Krishnamurthy
NCT06234507
ActivePI: Dr. Jegan Thomas
Your support powers genomic profiling and liquid biopsy research that helps doctors detect lung cancer earlier and choose the most effective treatment for each patient.
Donate Now
.png&w=96&q=75){kind=small}